{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:24:24Z","timestamp":1794673464886,"version":"4.9.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. We present the efficacy and safety of AN+AD (brentuximab vedotin [BV] and nivolumab in combination with doxorubicin and dacarbazine) in patients with early-stage cHL. In this phase 2 study, patients with nonbulky (&amp;lt;10 cm) Ann Arbor stage I or II cHL received 4 cycles of AN+AD. The primary end point was complete response (CR) rate at end of treatment (EOT) by investigator. At the time of this analysis, 154 patients received \u22651 dose of AN+AD. The objective response rate at EOT was 96% (95% confidence interval [CI], 91.7-98.6), and the CR rate was 92% (95% CI, 86.0-95.4). In the favorable (n = 56) and unfavorable (n = 97) subgroups, CR rates were 95% (95% CI, 85.1-98.9) and 91% (95% CI, 83.1-95.7), respectively. The proportion of patients with duration of CR of at least 2 years was 96% (95% CI, 90.9-98.4). At a median follow-up of 27.9 months, the estimated 2-year progression-free survival rate was 97% (95% CI, 92.0-98.8). Any-grade and grade \u22653 treatment-emergent adverse events occurred in 99% and 44% of patients, respectively; no events of febrile neutropenia were reported. Any-grade treatment-emergent immune-mediated adverse events occurred in 22% of patients. One disease-related death was reported after the safety reporting period. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy for patients with nonbulky, early-stage cHL. This trial was registered at www.clinicaltrials.gov as NCT03646123.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030190","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T19:05:24Z","timestamp":1767035124000},"page":"1713-1722","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-6816","authenticated-orcid":false,"given":"David J.","family":"Straus","sequence":"additional","affiliation":[{"name":"2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-6710","authenticated-orcid":false,"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"4Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0894","authenticated-orcid":false,"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"5Clinical Research Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-090X","authenticated-orcid":false,"given":"Eva","family":"Domingo Domenech","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Hospital Duran i Reynals, Institut Catal\u00e0 d\u2019Oncologia, Institut d'Investigaci\u00f3 de Ci\u00e8ncies Biom\u00e8diques de Bellvitge, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hess","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Division of Hematology and Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7766-6295","authenticated-orcid":false,"given":"Steven R.","family":"Schuster","sequence":"additional","affiliation":[{"name":"8Medical Oncology, UCHealth Poudre Valley Hospital, Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Linhares","sequence":"additional","affiliation":[{"name":"9Bone & Marrow Transplant Program, Miami Cancer Institute at Baptist Health, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitul","family":"Gandhi","sequence":"additional","affiliation":[{"name":"10Virginia Cancer Specialists, US Oncology Research, Gainesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-5238","authenticated-orcid":false,"given":"Harsh R.","family":"Shah","sequence":"additional","affiliation":[{"name":"11Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"12Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-6395","authenticated-orcid":false,"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[{"name":"13Division of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Hahn","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Royal Adelaide Hospital, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"15Clinical Hematology, Epworth HealthCare and University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchuan","family":"Guo","sequence":"additional","affiliation":[{"name":"16Pfizer, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2590-2477","authenticated-orcid":false,"given":"Griffith","family":"Davis","sequence":"additional","affiliation":[{"name":"16Pfizer, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ho","sequence":"additional","affiliation":[{"name":"16Pfizer, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"16Pfizer, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-156X","authenticated-orcid":false,"given":"Christopher A.","family":"Yasenchak","sequence":"additional","affiliation":[{"name":"17Willamette Valley Cancer Institute and Research Center\/US Oncology Research, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7219-5562","authenticated-orcid":false,"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[{"name":"18Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2026040911264532000_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2026040911264532000_bib2","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"2026040911264532000_bib3","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2026040911264532000_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","article-title":"Diagnostic, prognostic and therapeutic role of CD30 in lymphoma","volume":"10","author":"Pierce","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2026040911264532000_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"2026040911264532000_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10450","key":"2026040911264532000_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"15 suppl","key":"2026040911264532000_bib8","article-title":"Brentuximab vedotin-mediated immunogenic cell death","volume":"75","author":"Gardai","year":"2015","journal-title":"Cancer Res"},{"issue":"14 suppl","key":"2026040911264532000_bib9","article-title":"Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses","volume":"76","author":"Cao","year":"2016","journal-title":"Cancer Res"},{"issue":"7 suppl","key":"2026040911264532000_bib10","article-title":"CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors","volume":"83","author":"Heiser","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"2026040911264532000_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2026040911264532000_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026040911264532000_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"2026040911264532000_bib14","author":"Wahner","year":"2025"},{"issue":"7","key":"2026040911264532000_bib15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2026040911264532000_bib16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv"},{"key":"2026040911264532000_bib17","unstructured":"Opdivo (nivolumab)\n          . Prescribing information. Bristol Myers Squibb. 2025. Accessed 22 January 2026. https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf."},{"issue":"15","key":"2026040911264532000_bib18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"2026040911264532000_bib19","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2026040911264532000_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026040911264532000_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026040911264532000_bib22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"key":"2026040911264532000_bib23","unstructured":"German Hodgkin Study Group\n          . Disease Stages and Risk Factors. Accessed 21 January 2026. https:\/\/en.ghsg.org\/disease-stages."},{"issue":"1","key":"2026040911264532000_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","author":"Akhtari","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2026040911264532000_bib25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"issue":"27","key":"2026040911264532000_bib26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"2026040911264532000_bib27","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"2026040911264532000_bib28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-4899-3115-3_8","volume-title":"Modelling Survival Data in Medical Research","author":"Collett","year":"1994","edition":"1st ed"},{"issue":"31","key":"2026040911264532000_bib29","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026040911264532000_bib30","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"2026040911264532000_bib31","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"2026040911264532000_bib32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"20","key":"2026040911264532000_bib33","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026040911264532000_bib34","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.18.01799","article-title":"Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID study","volume":"37","author":"Barrington","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026040911264532000_bib35","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron mission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026040911264532000_bib36","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"21","key":"2026040911264532000_bib37","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"2026040911264532000_bib38","author":"Abramson","year":"9-12  2023"},{"issue":"suppl 16","key":"2026040911264532000_bib39","first-page":"1","article-title":"Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab","volume":"43","author":"Lynch","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026040911264532000_bib40","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1182\/blood-2023-189652","article-title":"AHOD2131: a randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma","volume":"142","author":"Henderson","year":"2023","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/15\/1713\/2512057\/blood_bld-2025-030190-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/15\/1713\/2512057\/blood_bld-2025-030190-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:27:03Z","timestamp":1775748423000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/15\/1713\/557530\/Brentuximab-vedotin-and-nivolumab-in-combination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":40,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030190","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,9]]},"published":{"date-parts":[[2026,4,9]]}}}